Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
87.85
-4.46 (-4.83%)
At close: Mar 25, 2025, 4:00 PM
88.12
+0.27 (0.31%)
After-hours: Mar 25, 2025, 5:35 PM EST
Merck & Co. Revenue
In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth. Merck & Co. had revenue of $15.62B in the quarter ending December 31, 2024, with 6.79% growth.
Revenue (ttm)
$64.17B
Revenue Growth
+6.74%
P/S Ratio
3.64
Revenue / Employee
$855,573
Employees
75,000
Market Cap
221.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
MRK News
- 11 hours ago - Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug - Reuters
- 11 hours ago - Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Business Wire
- 4 days ago - Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy - Seeking Alpha
- 6 days ago - Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease - Business Wire
- 10 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewsWire
- 11 days ago - Drugmakers agree to participate in second round of price negotiations - Reuters
- 13 days ago - Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48 - Business Wire
- 14 days ago - Merck prevails in Gardasil safety litigation - Reuters